The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
|Articles|September 10, 2012
VIDEO: Karen Ignagni Discusses Medicare's Hospital Readmission Penalties
Karen Ignagni, President and Chief Executive Officer, AHIP, feels Medicare is right to take on the challenge of hospital readmissions. Ms. Ignagni also discusses how the Medicare Advantage plans have done a better job with traditional fee-for-services programs and tackling high hospital readmission rates.
Advertisement
Karen Ignagni, President and Chief Executive Officer, AHIP, feels Medicare is right to take on the challenge of hospital readmissions. Ms. Ignagni also discusses how the Medicare Advantage plans have done a better job with traditional fee-for-services programs and tackling high hospital readmission rates.
This video was taken on September 10 at AHIP's 2012 Medicare and Medicaid Conference in Washington, DC.
Advertisement
Related to this article
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5